ALISO VIEJO, Calif., March 27 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make an investor presentation at the B. Riley & Co. 9th Annual Las Vegas Investor Conference at 4:00 p.m. PDT (7:00 p.m. EDT) on Wednesday, April 2, 2008. The conference is being held at the Palms Casino Resort April 2-4, 2008.
A live webcast of the Company's presentation at the conference will be available via a link provided at http://www.clarientinc.com/investor . An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days. Web participants are encouraged to go to the Company's website (http://www.clarientinc.com/investor ).
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. http://www.clarientinc.com
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc.
(NYSE: SFE) provides growth capital for entrepreneurial and innovative
technology and life sciences companies. Safeguard targets technology
companies in Software as a Service (SaaS), Technology-Enabled Services and
Internet-based Businesses, and life sciences companies in Molecular and
Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals
with capital requirements between $5 and $50 million. Safeguard
participates in expansion financings, corporate spin-outs, management
buyouts, recapitalizations, industry consolidations and early-stage
Allen & Caron, Inc.
|SOURCE Clarient, Inc.|
Copyright©2008 PR Newswire.
All rights reserved